NASDAQ:ASNDAscendis Pharma A/S Stock Price, Forecast & News

Ascendis Pharma A/S's stock was trading at $118.53 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ASND shares have increased by 22.7% and is now trading at $145.49. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ascendis Pharma A/S.

Ascendis Pharma A/S is scheduled to release its next quarterly earnings announcement on Wednesday, August 26th 2020. View our earnings forecast for Ascendis Pharma A/S.

Ascendis Pharma A/S (NASDAQ:ASND) released its quarterly earnings data on Tuesday, May, 19th. The biotechnology company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.43) by $0.11. The biotechnology company earned $2.45 million during the quarter, compared to analyst estimates of $2.66 million. Ascendis Pharma A/S had a negative return on equity of 36.56% and a negative net margin of 2,231.94%. View Ascendis Pharma A/S's earnings history.

11 brokers have issued 1-year price objectives for Ascendis Pharma A/S's shares. Their forecasts range from $145.00 to $208.00. On average, they expect Ascendis Pharma A/S's stock price to reach $172.09 in the next year. This suggests a possible upside of 18.3% from the stock's current price. View analysts' price targets for Ascendis Pharma A/S.

Media headlines about ASND stock have trended extremely negative this week, InfoTrie reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Ascendis Pharma A/S earned a daily sentiment score of -5.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutAscendis Pharma A/S.

Ascendis Pharma A/S saw a drop in short interest in May. As of May 15th, there was short interest totaling 1,930,000 shares, a drop of 5.9% from the April 30th total of 2,050,000 shares. Based on an average daily trading volume, of 228,000 shares, the days-to-cover ratio is currently 8.5 days. Currently, 4.3% of the shares of the company are short sold. View Ascendis Pharma A/S's Current Options Chain.

Some companies that are related to Ascendis Pharma A/S include Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Genmab A/S (GMAB), UCB (UCBJF), Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), Teva Pharmaceutical Industries (TEVA), GRIFOLS S A/S (GRFS), GALAPAGOS NV/S (GLPG), Beigene (BGNE), Catalent (CTLT) and Sarepta Therapeutics (SRPT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Neurocrine Biosciences (NBIX), Alexion Pharmaceuticals (ALXN), Exelixis (EXEL), NVIDIA (NVDA), GW Pharmaceuticals PLC- (GWPH), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (BMRN), Crispr Therapeutics (CRSP) and Enterprise Products Partners (EPD).

(ASND) raised $85 million in an initial public offering (IPO) on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager.

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

Ascendis Pharma A/S's stock is owned by a number of institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (10.24%), Orbimed Advisors LLC (6.85%), Vivo Capital LLC (4.17%), Janus Henderson Group PLC (3.89%), Wellington Management Group LLP (3.48%) and Franklin Resources Inc. (1.46%).

ASND stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., Camber Capital Management LP, Franklin Resources Inc., State Street Corp, Orbimed Advisors LLC, Ghost Tree Capital LLC, and Wellington Management Group LLP.

ASND stock was purchased by a variety of institutional investors in the last quarter, including Vivo Capital LLC, RA Capital Management L.P., Janus Henderson Group PLC, Spyglass Capital Management LLC, Asymmetry Capital Management L.P., JPMorgan Chase & Co., New York State Common Retirement Fund, and ARS Investment Partners LLC.

Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ASND stock can currently be purchased for approximately $145.49.

Ascendis Pharma A/S has a market capitalization of $6.98 billion and generates $14.98 million in revenue each year. The biotechnology company earns $-244,180,000.00 in net income (profit) each year or ($5.25) on an earnings per share basis. Ascendis Pharma A/S employs 216 workers across the globe.

The official website for Ascendis Pharma A/S is www.ascendispharma.com.

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The biotechnology company can be reached via phone at 45-7022-2244 or via email at [email protected]